Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report

Yasutaka Mochizuka; Tomoyuki Fujisawa; Yusuke Inoue; Hironao Hozumi; Yuzo Suzuki; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Takafumi Suda

doi:10.1016/j.rmcr.2022.101632

Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report

Respir Med Case Rep. 2022 Mar 15:37:101632. doi: 10.1016/j.rmcr.2022.101632. eCollection 2022.

Authors

Affiliations

¹ Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
² Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Abstract

We report herein a case of trimethoprim-sulfamethoxazole (TMP-SMX) induced eosinophilic pneumonia in a 27-year-old woman with radiological features of bilateral nonsegmental airspace consolidation resembling cryptogenic organizing pneumonia at the peripheral lung fields. Organizing pneumonia with eosinophil infiltration in the lung specimens and marked eosinophilia in the peripheral blood and bronchoalveolar lavage fluid were observed. Discontinuation of TMP-SMX improved eosinophilia and radiological abnormality, which confirmed the association between the use of TMP-SMX and onset of eosinophilic pneumonia. Although TMP-SMX induced eosinophilic pneumonia is not common, clinician should be aware that drug-induced eosinophilic pneumonia could happen during the course of TMP-SMX administration.

Keywords: Adverse reaction; Eosinophilic pneumonia; Organizing pneumonia; Trimethoprim-sulfamethoxazole.

Publication types

Case Reports